-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BkyhrGNdHFFtRtaknI2KYUunybqWa6vlJ32ghBFlfo8TSvq22sW0dyyObvFzqI/4 X3eNVzk34Ig3gfEQ5LzqLA== 0001169232-07-002848.txt : 20070703 0001169232-07-002848.hdr.sgml : 20070703 20070703131729 ACCESSION NUMBER: 0001169232-07-002848 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20070702 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20070703 DATE AS OF CHANGE: 20070703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: E-Z-EM, Inc. CENTRAL INDEX KEY: 0000727008 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 111999504 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-13003 FILM NUMBER: 07959246 BUSINESS ADDRESS: STREET 1: 1111 MARCUS AVENUE STREET 2: SUITE LL-26 CITY: LAKE SUCCESS STATE: NY ZIP: 11042 BUSINESS PHONE: 5163338230 MAIL ADDRESS: STREET 1: 1111 MARCUS AVENUE STREET 2: SUITE LL-26 CITY: LAKE SUCCESS STATE: NY ZIP: 11042 FORMER COMPANY: FORMER CONFORMED NAME: EZ EM INC DATE OF NAME CHANGE: 19920703 8-K 1 d72299_8k.htm CURRENT REPORT Form 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549
_________________

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 2, 2007

                                    E-Z-EM, INC.                                    
(Exact Name of Registrant as Specified in its Charter)

                                    Delaware                                    
(State or Other Jurisdiction of Incorporation)


                  0-13003                  
(Commission File Number) 		                    11-1999504                    
(IRS Employer Identification No.)

   1111 Marcus Avenue, Lake Success, New York              
   (Address of Principal Executive Offices) 		        11042        
(Zip Code)

                                  (516) 333-8230                                  
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 8.01. Other Events.

On July 2, 2007, E-Z-EM, Inc. (the “Company”) issued a press release to announce that Tyco Healthcare Group LP had filed a lawsuit against the Company in the Federal District Court in Texas alleging patent infringement related to the Company’s Empower®CT and Empower®CTA injector systems. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.


Item 9.01. Financial Statements and Exhibits.

(d)       Exhibits.

99.1  Press release dated July 2, 2007.





2



SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: July 3, 2007 E-Z-EM, INC.
(Registrant)


By:   /s/ Peter J. Graham                              
        Peter J. Graham
        Senior Vice President -
        Chief Legal Officer, Global Human
        Resources and Secretary






3



EXHIBIT INDEX


Exhibit No. Description of Exhibit

99.1 Press release dated July 2, 2007.





EX-99.1 2 d72299_ex99-1.htm PRESS RELEASE

Exhibit 99.1

 


 

Company Contacts:

Investor Relations Contacts:

E-Z-EM, Inc.

Lippert/Heilshorn & Associates, Inc.

Tom Johnson ( tjohnson@ezem.com )

Anne Marie Fields ( afields@lhai.com )

(800) 544-4624 x3317

(212) 838-3777

www.ezem.com

Bruce Voss ( bvoss@lhai.com )

 

(310) 691-7100

 

FOR IMMEDIATE RELEASE

 

E-Z-EM COMMENTS ON PATENT INFRINGEMENT LAWSUIT
RELATED TO EMPOWER INJECTOR

 

LAKE SUCCESS, N.Y., July 2, 2007—E-Z-EM, Inc., (NASDAQ: EZEM) today announced that Tyco Healthcare Group LP filed a lawsuit against the Company in the federal district court in Texas alleging patent infringement related to E-Z-EM’s Empower®CT and Empower®CTA injector systems. This lawsuit alleges infringement of a single U.S. patent concerning medical fluid injectors.

 

Commenting on the lawsuit, Anthony A. Lombardo, President and CEO said, “The Company respects the intellectual property rights of others and intends to vigorously defend against this action.”

 

About E-Z-EM, Inc.

 

E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company is the developer of VoLumen®—a patent-pending, next generation low density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and Positron Emission Tomography (PET/CT) studies. The Company also offers Empower®—the only family of CT injectors on the market with patented EDA™ technology that can help detect contrast extravasation—and offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system. The Company is also the exclusive world-wide manufacturer and marketer of RSDL for first-responder organizations and military services. RSDL is a patented, broad-spectrum liquid chemical warfare (CW) agent decontaminant, that neutralizes or removes chemical agents from skin on contact, leaving a non-toxic residue that can be rinsed off with water.

 

The statements made in this document contain certain forward-looking statements. Words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates” or variations of such words and similar expressions, are intended to identify such forward-looking statements. The forward-looking statements contained in this release may involve numerous risks and uncertainties, known and unknown, beyond the Company’s control. Such risks and uncertainties include: the ability of the Company to develop its products; the outcome and impact of any lawsuit involving Tyco Healthcare Group LP; future actions by the FDA or other regulatory agencies, overall economic conditions, general market conditions, price increases of raw materials and components, foreign currency exchange rate fluctuations as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Annual Report on Form 10-K for the fiscal year ended June 3, 2006 and its Form 10-Q for the quarter ended March 3, 2007. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements, and investors are cautioned not to place undue reliance on the forward-looking statements included in this release.

 

# # #

 

 GRAPHIC 3 img1.jpg GRAPHIC begin 644 img1.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH MHH`****`"BBN9\;^+4\*:.DD4)N=1NG\BRMEZR2'^@[U=.G*I-0CNQ-V5S6U M?7-+T"T^U:K?0VL78R-@L?0#J3]*YVW\>MJC;M$\.ZK?VQQMN?+$,;?0N1D5 MB:+H.CV>H?VGXUU6WU'Q&0'=;A@8[7(R%1>@QZUK3>*+;5W8)K$6F:8F?G4X MGG`ZD9^XOOU/M6E2KA:/NKWY>ME_G\[KT.JC@<16][E:CWL_Z?R-FTUZ_D=A M>^'[NS48P3+&^?P5JW58.H8=#7DLMMX:N-,O-3NIH3=R@"U@>5F>-2PPSY.2 MYZGT'%=)%JNA:'?V[Z9JD(L97\N>U\S*(3T=<_=YZCI@UQO$QD[\J2\G_F=M M3*G%6@Y-Z_9LKI)[W?>RTLV=O16;WBMVN=R\AD7.2/RKY6N M_''BJ[O9[G^W-5B$TC.(X[AU5`3G``.`!7IX/`SQ2;B[)'C5)^S=FM3Z[HKX M^_X3#Q5_T,.L?^!4G^-=IX4\3>(M.\(^(/$EYJVI7!"K8V*3RO(OG.!M1\2>([^>YC^>2)9%Y6.,')& M!W.?RKQVY^(OC.YNYIUU:^B61RXC3(5`3P!QVK"EEM2I.4$U[O4IU4DF?5U% M?)G_``G_`(U_Z#>H?F:Z?1/&?BJT\'ZWKE[JE[+(Q2QL5DY`E;YG?&/X5'YF MM9Y14@K\R$JR?0^C**^4H_B'XX>1$&M7N68+]P=SCTKW+XD^,IO"7A6,6I9M M5O%\N`A<[.!N<_3/YFL:V75:)?[8A8;WLS:LA'!(;?ND@D_P"Z*35=<&I3VVG_`/".:FJ;A/<1_9UW/&IX'7H6 MQGV!J[9MXB37=2C"Z8+EQ%(0S/@KMV@KQTR#5>WO-:@GUC69FTM$CD\B1Y&? M"B,8PO'=F/XUYKN]WOY=CZ.*A%KEBO=2M[SW=OZ7HB/4==%]J%C:CPYJ0$4@ MNIH_(7>57.SC/3=_*GZEKRW4UG;+X;U)'\]9V4VZ;F1#DXY]=OYTV*]US2UD MU.ZCL!>ZDRLELQ>KZ_=W\D<[X^\83Z%H^D:Y;6$MM.EV\ M'V.[7:)8RAW9`/3H1[BN+_X7QJ7_`$`-/_,USWQ.\7([9P,>U.\/)\-QHEN=?FU,ZD6_<^ M5JU>>HW#1'0)\=-5ED6./P_I[.Y"JHWVNG:*+W53!:1QQAY]V`J M-CG]:\9\-V?PN?4)=1T\:E(^E0F^?[0P"`)C&*-?\`%^Z]OM#M+/2MI"3#.Z1_]D'MUYKPGP:OA6*_%YXHN)FA MB;*6D,9;S#_M'T]J^CO"/C70_%0GM]$298[15#!H=BJ#T`_*HQ]"G1ARTZ?J M]1TY.3NV4/B-X\3P+IUF8K2.ZN+J0JL+-M`4#D_J!^->=?\`"_+O_H7;3_OZ M?\*YGXN:_P#V[X]NDC?=;V`^RQ\\9'WC_P!]9_*J'AR'P*VF%O$EUJRWQD.$ MLU78J=N2.371A\#1A0C*K!MOM?J3*I)RLF=J/CU>NP5/#EH68X4>8>2?PKHO M&WQ:E\+:Q%I46D6\\R6Z2W(=R!'(PSM''.!CGWKF?"VE?#.\UV.:PEUV22Q1 MKU_M"KY2K'\Q+X&<=/QK@(S<>-/'.]\B34KPN_\`L(3D_DH_2G'"X:=2_(TH MK6]_\_4.>26YZ-#\=KO[7%'/H-G$A=0[;SE5.,G\N:==_'RY:[F%OH5O);JY M\II)#N*YX)]*\BU*9+C4[N:,`1O*Q0>BYX'Y8JY?67]F:5:1RC%W>K]H93U2 M+^`?4\M],5T?V?A=+PW]2/:3[GLGA+XMZEXH\3V6D1Z!:*L[?O'5R2B`99J] MDKQ;X"^'/+M;[Q%,GS2G[-;Y'\(Y8_G@?A7M->!F"I1K.%)62_,Z:5W&["BB MBN$T"BBB@`HK+?0+.21G,M\"Q).+Z8#\@W%-_P"$=LO^>VH?^!\W_P`54WEV M-^6C_,_N_P"":U%9/_".V1_Y;:A_X'S?_%4?\(Y8_P#/6_\`_`^;_P"*HO+L M'+1_F?W?\$UJ*R?^$=LATEO_`/P/F_\`BJQ[8Z5=Z5/J$(UAHX96A*"]EWLP M;:0!OYYJ7)K?^OP-(4(35XM]%LNNW4W-4TA-0:*>.>6UO(<^5<18W`'J"#PP M/H:XJ^TRZLKAO[0UJ^,"7#76R'2RR^8?XN,@XZCT-=38:58:A80W:-JD:RJ& M"2WLRL/J-_%6?^$>L_\`GMJ'_@?-_P#%4*,9.\HW^=OT-X8F5!.G&;TTUC%V M^]G)6GB'2].D:XTS0_$&KW\HPUP]H^[V!9\!1]*@O]"\9>-X9AK#0Z-IX0F+ M38I/,:9\<>:X_ASC('7TKIK^RTW3I;..1]49KJ80QA+Z8\X)R?GZ8!J33]*T M_4M/ANT.JQI*,A)KV96'/<;ZZJ>*5)VHP2?=N[_*WX7,*M)5%[6K.33\E_\` M)>1XP?@)XC)R=3TS)Y."_P#\31_PH/Q%_P!!/3?S?_XFOM__P"! M\W_Q5'_".V7_`#VU#_P/F_\`BJZO[7Q?D76?P?UNP\%:CI, M&H6(OM1N8S/+EPH@0$A!QU+'GCI6!_PH/Q%_T$]-_-__`(FO8[&PTS4+B]AB M?4P;2;R79KZ;!;`/'S^]7?\`A';(]9M0_P#`^;_XJHAFN*5VK:_UV+GA:$7R MRD_N_P"">'_\*#\1?]!/3?S?_P")KU/P1X,G\&^#9M/AF@?5)M\CS#.SS",+ MVS@PTNWU6VT]GU+SKA'D5A?3;55<9)^?CJ*(+/2[G59=/BEU-GCA28 MO]NFV%6Z8._KQ6=?,L16CR3M:_\`70N.#I17,F]K[=+V[]SQ]_@-XEED>235 M--9W8LS%GY)Y/\--_P"%!^(O^@GIOYO_`/$U[-9Z5I]ZUR%_M6/R)C"?,O)A MN(QROS\CGK5K_A'+'_GK?_\`@?-_\56ZS?%O:W]?(SEA,/%V64ET M]E)!:%"V$D<8W'(]/3UKTT>';(=)M0_\#YO_`(J@^';(]9M0_P#`^;_XJLY9 MEB9)IVUW#V&'_F?W?\$\;TCX"ZG%JMH^JZA926*.&G2(L6=1V&0.M2^(/@SX MFUS7;W47U+35$TA\M,N-B#A5^[V``KU*^T_2]/FLXI6U-FNYA#'LOIC@D$Y/ MS],`TL=EIJ:\-.4ZD;A(1<[C>RE-N[`!R_KVQ3_M;$\_,VK[?UH7]2I.-TW; M?9=/F7O#FBP^'O#UCI4&-MM$$)'\3=S^)S6I1THKCE)R;D]V8I6"BBBD`444 M9H`**,T9H`**,T9H`*\YL'FM?AY?7A+1D/.;=@2I:21RH?(]">/QKT;-5Y;& MTGL_LDMM$]L`!Y3*"O'(X_"LYPYM5YG9A<4J*Y9*Z;B_DKW^^YY[JM[7"H/48!R/I6Y= M!M*M)=334[J::PLD1H3<$Q&4H`,KWZ[B3ZUU!T/2C$(SIUML$?E!?+&-F<[? MIGFH9/#>DRWYO'M$+L"'3^!R5VY*]"=I(H5&2+EF-";V:6NFFJ;O;\S,AEN] M%T36=5N;@S2"/S$B+[]FU,#/8%CR0..13?"TTTFIZL\MY+/%;K##\SDKYFS= M(P'N6_2NACTZRAL#8QVL2VA4J80@VD'J,4MO86=HLBV]K%$LOWPB`!N,<_A6 MBIM-/L<I/#N^5R[XCR._`S M["KLM[>V3QRWE\^R[B\Z1%ER0D418]#@%V(X'8"NW73+!#\MG`O[GR.(P/W? M]SZ>U0C0M)6WCMQIUMY,>[8GEC"[A@_F*S5&26YURS*A*3DX?EMJU]S/.IFF MNM/9;BZEDN?L-K9^89#N,D[[WY_W<<>U7HG:/Q.A@G>&W.H^2,2'YH;:+D$] MQDD5W7]C:9S_`*!;\E"?W8ZI]W\NU/\`[,L-R,+.`%"Y4B,<%_O'\>_K25!] MRI9K3::479W[=4OU5S@M.N]1U6PBTZ&\9&GMVNI)GF.4\R4A> M\,03WM[>ZK)>W+P_:)H8(6D)0H"%#?7Y3^=;:Z+I:26SK86X:U7;`1&/W8]! MZ5;@@AMH1%!$D48R0B*`!DY/`]S5PI--.3.?$X^$XRC2C:_IUW_3T//K>^U& M:X32S/2]@BDWDNS!AM.[KA1WILVM7IA34C<2C*7DSJ'("0H#'&,>I?!S MUR:]!6V@1T=84#(&"D+R,G)Q]:B&F6`CEC^QP>7,1]>:7L9=RUF M-&]W3_IWO^:^:.`N3=:+)9R3W4MS=VNGR7Q$[9VS,JQ*![9W&MGPS-;1:]J) MEO/,F=H[2$R/EI6C3=(1^+'\JZ>?3K&ZD>2>TAE=XO)8N@)*9SM^E-CTK3X9 MEFCLH$D5BZLL8!#$8)'X<4*DU*Z%4S"G4I.$D[M6TMWNOQ_!ERBC-&:Z#R`H 'HS1F@#__V3\_ ` end -----END PRIVACY-ENHANCED MESSAGE-----